Tania Cabielles
Acute Care · Miami, FLNPI 1831243997
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 254 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 19.6% — the pattern of someone who eats at a lot of different presentations. Among acute care clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 254 payments — averaging $18.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$940
- AbbVie$539
- Boehringer Ingelheim$425
- Novo Nordisk$419
- AstraZeneca$255
- Bayer$245
- plus $2K from 29 others
What the payments were for
- Food & beverage$4,785100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 59 | $940 |
| AbbVie | 31 | $539 |
| Boehringer Ingelheim | 19 | $425 |
| Novo Nordisk | 23 | $419 |
| AstraZeneca(2 entities) | 13 | $255 |
| Bayer | 11 | $245 |
| Corcept Therapeutics | 12 | $236 |
| Sumitomo Pharma America, Inc. | 8 | $189 |
| Pfizer | 9 | $164 |
| Amgen | 8 | $147 |
| Xeris Pharmaceuticals, Inc. | 7 | $143 |
| Esperion Therapeutics, Inc. | 5 | $100 |
| Exact Sciences | 5 | $97 |
| Abbott | 5 | $95 |
| Astellas Pharma US Inc | 5 | $90 |
| Edwards Lifesciences | 2 | $82 |
| Sunovion Pharmaceuticals Inc. | 3 | $70 |
| Insulet Corporation | 3 | $64 |
| Tandem Diabetes Care, Inc. | 2 | $56 |
| Novartis | 4 | $55 |
| Amarin Pharma, Inc. | 3 | $48 |
| Merck | 2 | $46 |
| Ultragenyx Pharmaceutical Inc. | 2 | $40 |
| Dexcom, Inc. | 2 | $34 |
| E.r. Squibb & Sons, L.L.C. | 1 | $24 |
| GSK | 1 | $23 |
| IBSA Pharma Inc. | 1 | $22 |
| Corium, LLC | 1 | $20 |
| Ardelyx, Inc. | 1 | $19 |
| Daiichi Sankyo Inc. | 1 | $18 |
| Phadia US Inc. | 1 | $18 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $17 |
| Eisai Inc. | 1 | $16 |
| Otsuka America Pharmaceutical, Inc. | 1 | $15 |
| Johnson & Johnson | 1 | $15 |
How this compares
$4,785 in reported general payments places this provider in the 95th percentile of 1,150 acute care providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 41 | $47,380 |
| EliquisApixaban | 25 | $35,188 |
| JardianceEmpagliflozin | 13 | $21,161 |
| OzempicSemaglutide | 20 | $19,043 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 22 | $14,227 |
| SymbicortBudesonide/Formoterol Fumarate | 26 | $8,969 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $7,569 |
| Atorvastatin Calcium | 164 | $1,399 |
| SynthroidLevothyroxine Sodium | 17 | $1,235 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $1,192 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 12 | $910 |
| Omeprazole | 66 | $839 |
| Losartan Potassium | 111 | $775 |
| Levothyroxine Sodium | 86 | $640 |
| Metoprolol Succinate | 53 | $557 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $940 | $47,38041 claims |
| PfizerEliquis | $164 | $35,18825 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $23 | $21,79633 claims |
| Boehringer IngelheimJardiance | $425 | $21,16113 claims |
| Novo NordiskOzempic | $419 | $19,04320 claims |
| AstraZenecaSymbicort | $255 | $8,96926 claims |
| AbbVieSynthroid | $539 | $1,23517 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,150 acute care providers in Florida.
Other acute care in Miami
- Yvette NaranjoMiami$12K
- Yuri CarmonaMiami$10K
- Monica RamirezMiami$9K
- Rosa Canete-YohamMiami$9K
- Julio AcostaMiami$9K
- Uday DasariMiami$7K
- Julissa WilliamsMiami$7K
- Michelle ViteriMiami$6K
- Marie RenoitMiami$6K
- Rebecca JuliaoMiami$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.